These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34069899)

  • 1. Effects of (a Combination of) the Beta
    Maarsingh H; Oldenburger A; Han B; Zuidhof AB; Elzinga CRS; Timens W; Meurs H; Sopi RB; Schmidt M
    Cells; 2021 May; 10(5):. PubMed ID: 34069899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.
    Cazzola M; Calzetta L; Puxeddu E; Ora J; Facciolo F; Rogliani P; Matera MG
    Respir Res; 2016 Jun; 17(1):70. PubMed ID: 27296533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD.
    Shimizu K; Seto R; Makita H; Suzuki M; Konno S; Ito YM; Kanda R; Ogawa E; Nakano Y; Nishimura M
    Respir Med; 2016 Oct; 119():70-77. PubMed ID: 27692151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study.
    Blais CM; Davis BE; Cockcroft DW
    Respir Res; 2017 Aug; 18(1):146. PubMed ID: 28768531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between glycopyrronium and indacaterol on cholinergic neurotransmission and contractile response in bovine trachealis.
    Baroffio M; Barisione G; Brusasco V
    Respir Res; 2017 Jul; 18(1):145. PubMed ID: 28754132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
    Ulrik CS
    Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH; Rabe KF; Welte T
    Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of indacaterol on the LPS-evoked changes in fluid secretion rate and pH in swine tracheal membrane.
    Aritake H; Tamada T; Murakami K; Gamo S; Nara M; Kazama I; Ichinose M; Sugiura H
    Pflugers Arch; 2021 Jun; 473(6):883-896. PubMed ID: 34031755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
    Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
    Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
    Rossi A; Zanardi E; Poletti V; Cazzola M
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1383-92. PubMed ID: 26229457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
    Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational Study Searching for Synergy between Glycopyrronium and Indacaterol.
    Cazzola M; Calzetta L; Segreti A; Facciolo F; Rogliani P; Matera MG
    COPD; 2015 Apr; 12(2):175-81. PubMed ID: 25222881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
    Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
    Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
    Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
    Mahler DA; Kerwin E; Ayers T; FowlerTaylor A; Maitra S; Thach C; Lloyd M; Patalano F; Banerji D
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1068-79. PubMed ID: 26177074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium.
    Pelaia G; Maselli R; Matera MG
    Pharmacology; 2014; 94(5-6):249-58. PubMed ID: 25471458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.
    Blair HA
    Drugs; 2021 Apr; 81(6):709-719. PubMed ID: 33871819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol.
    Aparici M; Gavaldà A; Ramos I; Carcasona C; Otal R; Fernández-Blanco JA; Montero JL; García VM; López R; De Alba J; Doe C; Puig C; Vilella D; Miralpeix M
    Eur J Pharmacol; 2016 Jan; 770():61-9. PubMed ID: 26656755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.
    Battram C; Charlton SJ; Cuenoud B; Dowling MR; Fairhurst RA; Farr D; Fozard JR; Leighton-Davies JR; Lewis CA; McEvoy L; Turner RJ; Trifilieff A
    J Pharmacol Exp Ther; 2006 May; 317(2):762-70. PubMed ID: 16434564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.